Sara M. Tolaney on Neoadjuvant Treatment Considerations for Triple-Negative Breast Cancer
There are many clinical trial opportunities, Tolaney says, before surgery.
BY Sara M. Tolaney
PUBLISHED September 18, 2015
Sara M. Tolaney, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer.
“[There are] lots of potential clinical trial opportunities prior to surgery because we do have this question about whether or not platinum therapy is beneficial,” Tolaney says.